$SNGX
SOLIGENIX, INC.

2024 Q4 Form 10-Q Financial Statement

#000155837024015054 Filed on November 08, 2024

View on sec.gov

Income Statement

Concept 2024 Q4 2024 Q3
Revenue $0.00
YoY Change -100.0%
Cost Of Revenue $0.00
YoY Change -100.0%
Gross Profit $0.00
YoY Change -100.0%
Gross Profit Margin
Selling, General & Admin $896.6K
YoY Change -7.57%
% of Gross Profit
Research & Development $968.7K
YoY Change 17.27%
% of Gross Profit
Depreciation & Amortization $1.590K
YoY Change
% of Gross Profit
Operating Expenses $1.865M
YoY Change 3.68%
Operating Profit -$1.865M
YoY Change 4.84%
Interest Expense $78.84K
YoY Change 18.8%
% of Operating Profit
Other Income/Expense, Net $145.9K
YoY Change 25.35%
Pretax Income -$1.719M
YoY Change 3.41%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$1.719M
YoY Change 3.41%
Net Earnings / Revenue
Basic Earnings Per Share -$0.78
Diluted Earnings Per Share -$0.78
COMMON SHARES
Basic Shares Outstanding 2.509M 2.280M
Diluted Shares Outstanding 2.204M

Balance Sheet

Concept 2024 Q4 2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $9.840M
YoY Change -4.46%
Cash & Equivalents $9.840M
Short-Term Investments
Other Short-Term Assets $466.7K
YoY Change -19.53%
Inventory
Prepaid Expenses $340.3K
Receivables $0.00
Other Receivables $0.00
Total Short-Term Assets $10.31M
YoY Change -6.06%
LONG-TERM ASSETS
Property, Plant & Equipment $7.162K
YoY Change -47.01%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $22.78K
YoY Change -62.03%
Total Long-Term Assets $170.1K
YoY Change -48.61%
TOTAL ASSETS
Total Short-Term Assets $10.31M
Total Long-Term Assets $170.1K
Total Assets $10.48M
YoY Change -7.31%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $891.2K
YoY Change -38.99%
Accrued Expenses $1.363M
YoY Change -42.89%
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due $2.059M
YoY Change 37.29%
Total Short-Term Liabilities $4.530M
YoY Change -17.95%
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change -100.0%
Other Long-Term Liabilities $11.54K
YoY Change -91.76%
Total Long-Term Liabilities $11.54K
YoY Change -99.26%
TOTAL LIABILITIES
Total Short-Term Liabilities $4.530M
Total Long-Term Liabilities $11.54K
Total Liabilities $4.542M
YoY Change -35.87%
SHAREHOLDERS EQUITY
Retained Earnings -$231.0M
YoY Change 3.17%
Common Stock $2.295K
YoY Change -77.89%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $5.935M
YoY Change
Total Liabilities & Shareholders Equity $10.48M
YoY Change -7.31%

Cashflow Statement

Concept 2024 Q4 2024 Q3
OPERATING ACTIVITIES
Net Income -$1.719M
YoY Change 3.41%
Depreciation, Depletion And Amortization $1.590K
YoY Change
Cash From Operating Activities -$2.910M
YoY Change 8.2%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 3.293M
YoY Change -2037.32%
NET CHANGE
Cash From Operating Activities -2.910M
Cash From Investing Activities
Cash From Financing Activities 3.293M
Net Change In Cash 383.0K
YoY Change -113.39%
FREE CASH FLOW
Cash From Operating Activities -$2.910M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2024Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.78
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.56
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.84
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-10.05
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
2203929
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
648860
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1376568
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
429773
dei Entity Central Index Key
EntityCentralIndexKey
0000812796
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Amendment Flag
AmendmentFlag
false
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
2295304
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
648761
CY2024Q2 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.0625
CY2024Q2 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.0625
CY2024Q2 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.0625
CY2024Q2 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.0625
CY2024Q2 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.0625
CY2024Q2 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.0625
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-14778
dei Entity Registrant Name
EntityRegistrantName
SOLIGENIX, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
41-1505029
dei Entity Address Address Line1
EntityAddressAddressLine1
29 EMMONS DRIVE
dei Entity Address Address Line2
EntityAddressAddressLine2
SUITE B-10
dei Entity Address City Or Town
EntityAddressCityOrTown
PRINCETON,
dei Entity Address State Or Province
EntityAddressStateOrProvince
NJ
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
08540
dei City Area Code
CityAreaCode
609
dei Local Phone Number
LocalPhoneNumber
538-8200
dei Security12b Title
Security12bTitle
Common Stock, par value $.001 per share
dei Trading Symbol
TradingSymbol
SNGX
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
2509499
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
9840177
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
8446158
CY2023Q4 us-gaap Unbilled Receivables Current
UnbilledReceivablesCurrent
171254
CY2023Q4 us-gaap Receivables Long Term Contracts Or Programs
ReceivablesLongTermContractsOrPrograms
23894
CY2024Q3 us-gaap Deferred Costs Current
DeferredCostsCurrent
126385
CY2024Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
340330
CY2023Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
866014
CY2024Q3 us-gaap Assets Current
AssetsCurrent
10306892
CY2023Q4 us-gaap Assets Current
AssetsCurrent
9507320
CY2024Q3 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
22777
CY2023Q4 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
22777
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
7162
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
11927
CY2024Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
140148
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
229834
CY2023Q4 us-gaap Capitalized Contract Cost Net Noncurrent
CapitalizedContractCostNetNoncurrent
25468
CY2024Q3 us-gaap Assets
Assets
10476979
CY2023Q4 us-gaap Assets
Assets
9797326
CY2024Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
891227
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1111226
CY2024Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1363235
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2418002
CY2024Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
84362
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
251115
CY2024Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
132114
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
121765
CY2024Q3 us-gaap Convertible Debt Current
ConvertibleDebtCurrent
2059309
CY2023Q4 us-gaap Convertible Debt Current
ConvertibleDebtCurrent
2250000
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
4530247
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
6152108
CY2023Q4 us-gaap Long Term Debt
LongTermDebt
1010934
CY2024Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
11544
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
111862
CY2024Q3 us-gaap Liabilities
Liabilities
4541791
CY2023Q4 us-gaap Liabilities
Liabilities
7274904
CY2024Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
350000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
350000
CY2024Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2024Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
75000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
75000000
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
2295304
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
648761
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
2295
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
649
CY2024Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
236878806
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
228203706
CY2024Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
37473
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
22243
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-230983386
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-225704176
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
5935188
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
2522422
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
10476979
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
9797326
CY2023Q3 us-gaap Revenues
Revenues
130440
us-gaap Revenues
Revenues
119371
us-gaap Revenues
Revenues
594547
CY2023Q3 us-gaap Cost Of Revenue
CostOfRevenue
110441
us-gaap Cost Of Revenue
CostOfRevenue
119371
us-gaap Cost Of Revenue
CostOfRevenue
520502
CY2023Q3 us-gaap Gross Profit
GrossProfit
19999
us-gaap Gross Profit
GrossProfit
74045
CY2024Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
968689
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
826015
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2564887
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2535165
CY2024Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
896547
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
973040
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3162115
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3098949
CY2024Q3 us-gaap Operating Expenses
OperatingExpenses
1865236
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
1799055
us-gaap Operating Expenses
OperatingExpenses
5727002
us-gaap Operating Expenses
OperatingExpenses
5634114
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-1865236
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-1779056
us-gaap Operating Income Loss
OperatingIncomeLoss
-5727002
us-gaap Operating Income Loss
OperatingIncomeLoss
-5560069
CY2024Q3 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
575
CY2023Q3 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-3046
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
2257
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
310
CY2024Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
78836
CY2023Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
66363
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
143603
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-97399
CY2023Q3 sngx Uk Research And Development Incentives
UkResearchAndDevelopmentIncentives
-4729
sngx Uk Research And Development Incentives
UkResearchAndDevelopmentIncentives
25488
sngx Uk Research And Development Incentives
UkResearchAndDevelopmentIncentives
-17386
CY2024Q3 sngx Employee Retention Credit Cares Act
EmployeeRetentionCreditCaresAct
66444
CY2023Q3 sngx Employee Retention Credit Cares Act
EmployeeRetentionCreditCaresAct
120771
sngx Employee Retention Credit Cares Act
EmployeeRetentionCreditCaresAct
66444
sngx Employee Retention Credit Cares Act
EmployeeRetentionCreditCaresAct
120771
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
43
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
43223
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-393791
CY2023Q3 sngx Fair Value Adjustment Of Convertible Debt
FairValueAdjustmentOfConvertibleDebt
72463
sngx Fair Value Adjustment Of Convertible Debt
FairValueAdjustmentOfConvertibleDebt
-260933
sngx Fair Value Adjustment Of Convertible Debt
FairValueAdjustmentOfConvertibleDebt
-387537
CY2024Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
145855
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
116354
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
447792
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
78037
CY2024Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-1719381
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-1662702
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-5279210
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-5482032
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-1161197
CY2024Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-1719381
CY2023Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-1662702
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-5279210
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-4320835
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.78
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.56
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.84
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-10.05
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
2203929
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
648860
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1376568
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
429773
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-1719381
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-1662702
us-gaap Net Income Loss
NetIncomeLoss
-5279210
us-gaap Net Income Loss
NetIncomeLoss
-4320835
CY2024Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
9874
CY2023Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
18257
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
15230
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-429
CY2024Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-1709507
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-1644445
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-5263980
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-4321264
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
2522422
sngx Adjustments To Additional Paid In Capital Warrants Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalWarrantsIssuedIssuanceCosts
7552457
us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
7177683
us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
254256
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
174268
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
15230
us-gaap Net Income Loss
NetIncomeLoss
-5279210
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
5935188
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-2470826
us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
73000
us-gaap Stock Issued During Period Value Purchase Of Assets
StockIssuedDuringPeriodValuePurchaseOfAssets
50000
sngx Stock Issued During Period Value Exercise Of Warrants
StockIssuedDuringPeriodValueExerciseOfWarrants
3299
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
229076
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-429
us-gaap Net Income Loss
NetIncomeLoss
-4320835
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
4221155
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
3464776
CY2024Q3 sngx Adjustments To Additional Paid In Capital Warrants Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalWarrantsIssuedIssuanceCosts
7552457
CY2024Q3 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
7177683
CY2024Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
56632
CY2024Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
9874
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-1719381
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
5935188
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
5800200
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
65400
CY2023Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
18257
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-1662702
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
4221155
us-gaap Profit Loss
ProfitLoss
-5279210
us-gaap Profit Loss
ProfitLoss
-4320835
us-gaap Cost Of Goods And Services Sold Depreciation And Amortization
CostOfGoodsAndServicesSoldDepreciationAndAmortization
4765
us-gaap Cost Of Goods And Services Sold Depreciation And Amortization
CostOfGoodsAndServicesSoldDepreciationAndAmortization
4964
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
89686
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
82500
us-gaap Share Based Compensation
ShareBasedCompensation
174268
us-gaap Share Based Compensation
ShareBasedCompensation
229076
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
73000
sngx Issuance Of Common Stock For Purchase Option
IssuanceOfCommonStockForPurchaseOption
50000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-393791
sngx Fair Value Adjustment Of Convertible Debt
FairValueAdjustmentOfConvertibleDebt
-260933
sngx Fair Value Adjustment Of Convertible Debt
FairValueAdjustmentOfConvertibleDebt
-387537
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
12518
us-gaap Increase Decrease In Accounts And Other Receivables
IncreaseDecreaseInAccountsAndOtherReceivables
-171254
us-gaap Increase Decrease In Accounts And Other Receivables
IncreaseDecreaseInAccountsAndOtherReceivables
-49079
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-525684
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
310229
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
-51879
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
-92092
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-89969
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-80458
us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
-1391432
us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
-2382708
us-gaap Increase Decrease In Other Employee Related Liabilities
IncreaseDecreaseInOtherEmployeeRelatedLiabilities
-166753
us-gaap Increase Decrease In Other Employee Related Liabilities
IncreaseDecreaseInOtherEmployeeRelatedLiabilities
-281149
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-6170761
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-6775896
sngx Proceeds From Issuance Of Common Stock Pursuant To Market Sales Agreement
ProceedsFromIssuanceOfCommonStockPursuantToMarketSalesAgreement
58436
sngx Proceeds From Issuance Of Common Stock Pursuant To Market Sales Agreement
ProceedsFromIssuanceOfCommonStockPursuantToMarketSalesAgreement
3091462
sngx Proceeds From Issuance Of Common Stock And Warrants
ProceedsFromIssuanceOfCommonStockAndWarrants
4741400
sngx Proceeds From Issuance Of Common Stock And Warrants
ProceedsFromIssuanceOfCommonStockAndWarrants
8495817
sngx Proceeds From Exercise Of Warrants
ProceedsFromExerciseOfWarrants
-4450172
sngx Proceeds From Exercise Of Warrants
ProceedsFromExerciseOfWarrants
-3299
sngx Payments Of Warrant Issuance Costs Upon Inducement
PaymentsOfWarrantIssuanceCostsUponInducement
374774
us-gaap Repayments Of Convertible Debt
RepaymentsOfConvertibleDebt
686436
us-gaap Repayments Of Convertible Debt
RepaymentsOfConvertibleDebt
7000000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
7519211
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
3709688
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
45569
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
5127
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
1394019
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-3061081
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
8446158
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
13359615
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
9840177
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
10298534
us-gaap Income Taxes Paid
IncomeTaxesPaid
42162
us-gaap Income Taxes Paid
IncomeTaxesPaid
13006
us-gaap Interest Paid Net
InterestPaidNet
183771
us-gaap Interest Paid Net
InterestPaidNet
488011
sngx Operating Lease Paid
OperatingLeasePaid
102300
sngx Operating Lease Paid
OperatingLeasePaid
99975
us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
254256
sngx Noncash Or Part Noncash Deferred Issuance Cost Reclassified To Additional Paid In Capital
NoncashOrPartNoncashDeferredIssuanceCostReclassifiedToAdditionalPaidInCapital
228161
sngx Noncash Or Part Noncash Deferred Issuance Cost Reclassified To Additional Paid In Capital
NoncashOrPartNoncashDeferredIssuanceCostReclassifiedToAdditionalPaidInCapital
2339
sngx Redemption Of Preferred Stock
RedemptionOfPreferredStock
43
sngx Stock Issuance Costs Included In Accounts Payable
StockIssuanceCostsIncludedInAccountsPayable
83810
sngx Stock Issuance Costs Included In Accounts Payable
StockIssuanceCostsIncludedInAccountsPayable
46180
sngx Issuance Cost Of Warrant Exercise
IssuanceCostOfWarrantExercise
7177683
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
2
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-230983386
us-gaap Net Income Loss
NetIncomeLoss
-5279210
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-6170761
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
9840177
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
8446158
CY2024Q3 sngx Working Capital Carrying Value
WorkingCapitalCarryingValue
5776645
CY2023Q4 sngx Working Capital Carrying Value
WorkingCapitalCarryingValue
3355212
CY2024Q2 us-gaap Share Price
SharePrice
6.40
CY2024Q3 sngx Class Of Warrant Or Right Percentage Of Existing Warrant Shares To New Warrant Share Issues
ClassOfWarrantOrRightPercentageOfExistingWarrantSharesToNewWarrantShareIssues
1.50
CY2024Q2 us-gaap Stock Issued During Period Shares Reverse Stock Splits
StockIssuedDuringPeriodSharesReverseStockSplits
0
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
2
us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
0
CY2023Q3 us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
0
us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
0
CY2024Q3 us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
0
CY2024Q3 sngx Adjustment To Estimated Accrued Clinical Trial Expenses
AdjustmentToEstimatedAccruedClinicalTrialExpenses
375000
sngx Adjustment To Estimated Accrued Clinical Trial Expenses
AdjustmentToEstimatedAccruedClinicalTrialExpenses
1300000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Rights
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights
25%
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Rights
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights
25%
sngx Share Based Compensation Arrangement Service Period
ShareBasedCompensationArrangementServicePeriod
P3Y
sngx Sharebased Compensation Expiration Period
SharebasedCompensationExpirationPeriod
P10Y
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0
CY2024Q3 us-gaap Foreign Currency Transaction Gain Loss Realized
ForeignCurrencyTransactionGainLossRealized
575
CY2023Q3 us-gaap Foreign Currency Transaction Gain Loss Realized
ForeignCurrencyTransactionGainLossRealized
-3046
us-gaap Foreign Currency Transaction Gain Loss Realized
ForeignCurrencyTransactionGainLossRealized
2257
us-gaap Foreign Currency Transaction Gain Loss Realized
ForeignCurrencyTransactionGainLossRealized
310
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1599718
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1594128
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Use of Estimates and Assumptions</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;">The preparation of financial statements requires management to make estimates and assumptions such as the fair value of warrants and stock options and to accrue for clinical trials in process that affect the reported amounts in the financial statements and accompanying notes. Actual results could differ from those estimates.</p>
CY2024Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
951029
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1993784
CY2024Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
412206
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
424218
CY2024Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1363235
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2418002
CY2024Q2 us-gaap Share Price
SharePrice
6.40
CY2024Q2 us-gaap Share Price
SharePrice
6.40
CY2024Q3 sngx Warrant Issuance Costs
WarrantIssuanceCosts
7500000
CY2024Q3 sngx Warrant Issuance Costs Financial And Legal Fees
WarrantIssuanceCostsFinancialAndLegalFees
400000
CY2024Q3 sngx Issuance Cost Of Warrant Exercise
IssuanceCostOfWarrantExercise
7200000
CY2022Q2 sngx Lease Rental Per Month
LeaseRentalPerMonth
11367
CY2024Q3 us-gaap Contractual Obligation Future Minimum Payments Due Remainder Of Fiscal Year
ContractualObligationFutureMinimumPaymentsDueRemainderOfFiscalYear
55617
CY2024Q3 us-gaap Contractual Obligation Due In Next Twelve Months
ContractualObligationDueInNextTwelveMonths
162250
CY2024Q3 us-gaap Contractual Obligation Due In Second Year
ContractualObligationDueInSecondYear
46000
CY2024Q3 us-gaap Contractual Obligation Due In Third Year
ContractualObligationDueInThirdYear
46000
CY2024Q3 us-gaap Contractual Obligation Due In Fourth Year
ContractualObligationDueInFourthYear
46000
CY2024Q3 us-gaap Contractual Obligation
ContractualObligation
355867
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
2
CY2023Q3 us-gaap Revenues
Revenues
130440
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-1865236
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-1779056
CY2024Q3 us-gaap Cost Of Goods And Services Sold Depreciation And Amortization
CostOfGoodsAndServicesSoldDepreciationAndAmortization
1589
CY2023Q3 us-gaap Cost Of Goods And Services Sold Depreciation And Amortization
CostOfGoodsAndServicesSoldDepreciationAndAmortization
1589
CY2024Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
145855
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
116354
CY2024Q3 us-gaap Share Based Compensation
ShareBasedCompensation
56632
CY2023Q3 us-gaap Share Based Compensation
ShareBasedCompensation
65400
us-gaap Revenues
Revenues
119371
us-gaap Revenues
Revenues
594547
us-gaap Operating Income Loss
OperatingIncomeLoss
-5727002
us-gaap Operating Income Loss
OperatingIncomeLoss
-5560069
us-gaap Cost Of Goods And Services Sold Depreciation And Amortization
CostOfGoodsAndServicesSoldDepreciationAndAmortization
4765
us-gaap Cost Of Goods And Services Sold Depreciation And Amortization
CostOfGoodsAndServicesSoldDepreciationAndAmortization
4964
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
447792
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
78037
us-gaap Share Based Compensation
ShareBasedCompensation
174268
us-gaap Share Based Compensation
ShareBasedCompensation
229076
CY2024Q3 us-gaap Assets
Assets
10476979
CY2023Q4 us-gaap Assets
Assets
9797326
CY2024Q3 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0001558370-24-015054-index-headers.html Edgar Link pending
0001558370-24-015054-index.html Edgar Link pending
0001558370-24-015054.txt Edgar Link pending
0001558370-24-015054-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
sngx-20240930.xsd Edgar Link pending
sngx-20240930x10q.htm Edgar Link pending
sngx-20240930xex31d1.htm Edgar Link pending
sngx-20240930xex31d2.htm Edgar Link pending
sngx-20240930xex32d1.htm Edgar Link pending
sngx-20240930xex32d2.htm Edgar Link pending
sngx-20240930_cal.xml Edgar Link unprocessable
sngx-20240930_def.xml Edgar Link unprocessable
sngx-20240930_lab.xml Edgar Link unprocessable
sngx-20240930_pre.xml Edgar Link unprocessable
sngx-20240930x10q_htm.xml Edgar Link completed